Last reviewed · How we verify
Placebo to Boceprevir
Boceprevir is a protease inhibitor that works by blocking the replication of the hepatitis C virus.
Boceprevir is a protease inhibitor that works by blocking the replication of the hepatitis C virus. Used for Chronic hepatitis C genotype 1 infection, Chronic hepatitis C genotype 1 infection in patients with compensated liver cirrhosis.
At a glance
| Generic name | Placebo to Boceprevir |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Protease inhibitor |
| Target | NS3/4A protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Boceprevir specifically targets the NS3/4A protease of the hepatitis C virus, preventing the virus from replicating. This leads to a reduction in viral load and an improvement in liver function.
Approved indications
- Chronic hepatitis C genotype 1 infection
- Chronic hepatitis C genotype 1 infection in patients with compensated liver cirrhosis
Common side effects
- Fatigue
- Nausea
- Headache
- Diarrhea
- Abdominal pain
Key clinical trials
- Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003) (PHASE2)
- The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160) (PHASE3)
- Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063) (PHASE3)
- A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4) (PHASE2)
- Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED) (PHASE3)
- Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED) (PHASE3)
- Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED) (PHASE3)
- A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to Boceprevir CI brief — competitive landscape report
- Placebo to Boceprevir updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI